Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis

被引：0
|
作者：
Germain Honvo
Jean-Yves Reginster
Véronique Rabenda
Anton Geerinck
Ouafa Mkinsi
Alexia Charles
Rene Rizzoli
Cyrus Cooper
Bernard Avouac
Olivier Bruyère
机构：
[1] University of Liège,Department of Public Health, Epidemiology and Health Economics
[2] WHO Collaborating Centre for Public Heath Aspects of Musculoskeletal Health and Aging,Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science
[3] King Saud University,Rheumatology Department
[4] IBN ROCHD University Hospital,Division of Bone Diseases
[5] Geneva University Hospitals and Faculty of Medicine,MRC Lifecourse Epidemiology Unit
[6] University of Southampton,National Institute for Health Research (NIHR) Musculoskeletal Biomedical Research Unit
[7] Southampton General Hospital,undefined
[8] University of Oxford,undefined
来源：
Drugs & Aging | 2019年 / 36卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：65 / 99
页数：34
相关论文
共 50 条
  • [1] Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis
    Honvo, Germain
    Reginster, Jean-Yves
    Rabenda, Veronique
    Geerinck, Anton
    Mkinsi, Ouafa
    Charles, Alexia
    Rizzoli, Rene
    Cooper, Cyrus
    Avouac, Bernard
    Bruyere, Olivier
    [J]. DRUGS & AGING, 2019, 36 (Suppl 1) : 65 - 99
  • [2] Symptomatic slow-acting drugs for osteoarthritis: what are the facts?
    Dougados, Maxime
    [J]. JOINT BONE SPINE, 2006, 73 (06) : 606 - 609
  • [3] ADVERSE EVENTS ASSOCIATED WITH SYMPTOMATIC SLOW-ACTING DRUGS IN OSTEOARTHRITIS (SYSADOAS): A SYSTEMATIC REVIEW AND STRATIFIED META-ANALYSIS OF RANDOMISED, PLACEBO-CONTROLLED TRIALS
    Honvo, G.
    Rabenda, V.
    Geerinck, A.
    Cooper, C.
    Reginster, J. -Y.
    Bruyere, O.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S561 - S562
  • [4] SYMPTOMATIC SLOW-ACTING DRUGS IN OSTEOARTHRITIS - A NOVEL THERAPEUTIC CONCEPT
    LEQUESNE, M
    [J]. REVUE DU RHUMATISME, 1994, 61 (02): : 75 - 79
  • [5] Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system
    Olivier Bruyère
    Nansa Burlet
    Pierre D Delmas
    René Rizzoli
    Cyrus Cooper
    Jean-Yves Reginster
    [J]. BMC Musculoskeletal Disorders, 9
  • [6] Assessment of the placebo effect of symptomatic slow-acting drugs given for osteoarthritis
    Villani, P
    Bouvenot, G
    [J]. PRESSE MEDICALE, 1998, 27 (05): : 211 - 214
  • [7] Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system
    Bruyere, Olivier
    Burlet, Nansa
    Delmas, Pierre D.
    Rizzoli, Rene
    Cooper, Cyrus
    Reginster, Jean-Yves
    [J]. BMC MUSCULOSKELETAL DISORDERS, 2008, 9 (1)
  • [8] Functional Disability and Symptomatic Slow-Acting Drugs for Osteoarthritis in Adults with Periodontitis
    Nik-Azis, Nik-Madihah
    Mohd, Nurulhuda
    Baharin, Badiah
    Fadzilah, Fazalina Mohd
    Haflah, Nor Hazla Mohamed
    Said, Mohd Shahrir Mohamed
    [J]. HEALTHCARE, 2023, 11 (05)
  • [9] Current status of symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) in Spain
    Bernad Pineda, Miguel
    [J]. REUMATOLOGIA CLINICA, 2016, 12 (04): : 181 - 183
  • [10] Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis
    Reginster, Jean-Yves
    Cooper, Cyrus
    Hochberg, Marc
    Pelletier, Jean-Pierre
    Rizzoli, Rene
    Kanis, John
    Abadie, Eric
    Maheu, Emmanuel
    Brandi, Maria Luisa
    Devogelaer, Jean-Pierre
    Branco, Jaime
    Herrero-Beaumont, Gabriel
    D'Hooghe, Pieter
    Bruyere, Olivier
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (05) : 1041 - 1045
12345